GlassScriptPhysician profile
Oswaldo Bisbal
NPI 1487686242
$2,401.66
in general payments reported to CMS, 2019-2025
15 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $222 · 2021: $69.87 · 2022: $1,210 · 2024: $117 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,210.23 | 2022 | |
| Abbvie INC. | $463.27 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.55 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $120.39 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.96 | 2019 | |
| Janssen Biotech, INC. | $63.66 | 2019-2025 | Tremfya, Simponi, Stelara |
| Qol Medical, LLC | $63.63 | 2019 | |
| Pfizer INC. | $58.97 | 2019-2025 | |
| Braintree Laboratories, INC. | $25.15 | 2024 | Suflave |
| Aimmune Therapeutics, INC. | $19.75 | 2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $19.19 | 2025 | Dupixent |
| Allergan, INC. | $17.08 | 2019 | |
| Merck Sharp & Dohme LLC | $16.89 | 2024 | Dificid |
| Shire North American Group INC | $15.87 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oswaldo Bisbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.